You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


FDA approves GSK’s Jemperli for dMMR endometrial cancer

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli for the treatment of patients with advanced endometrial cancer with a specific biomarker.